INmune Bio Unveils Phase 2 Alzheimer's Trial Results at CTAD Conference
INmune Bio Inc. will present Phase 2 trial results of XPro1595 for early Alzheimer's at the CTAD conference in San Diego, December 1-4, 2025. The first presentation will discuss the MINDFuL trial results, and the second will validate the EMACC through blood-based biomarkers. This announcement was originally published via EDGAR by INmune Bio.
INmune Bio Inc., a clinical-stage inflammation and immunology company, has announced two upcoming presentations at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) conference, scheduled to take place in San Diego, California, from December 1-4, 2025. The first presentation will cover results from the Phase 2 MINDFuL trial of XPro1595, a selective soluble TNF neutralizer, in patients with early Alzheimer’s disease with inflammation. This presentation is scheduled for December 1-2, 2025. The second presentation, set for December 4, 2025, will focus on the validation of the Early Mild Alzheimer’s Cognitive Composite (EMACC) through associations with blood-based biomarkers of Alzheimer’s disease. The results from these studies will be presented at the conference. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. INmune Bio Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-25-112136), on November 18, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
